. Cellular components of the atherosclerotic process synthesize and respond to PAF and atherosclerotic plaques have been shown to be rich in 8] .
We suggested, based on preliminary analyses of differential expression of phospho-proteins in monocyte extracts, that GSK-3␤ plays a prominent role in PAF induced

Experimental procedures Patient characteristics
Patient characteristics from whom monocytes were isolated are provided in Table 1 . Those 
with DM were either on diet therapy (n ϭ 10), metformin alone (n ϭ 10) or metformin and sulphonylurea (n ϭ 5). None of the individuals were on insulin or thiazolidinediones. Individuals were asked to hold all their medications on the morning of the blood draw.
Human monocyte separation
In compliance with Mayo Institutional Review Board and following informed consent, buffy coat was collected from 100 ml of blood from each participant by graded centrifugation and thoroughly mixed up with HBSS (without Ca
ϩϩ or
Trans-endothelial migration
Thick collagen was prepared as described [21] . Involvement of small GTPases on PAF activated monocyte migration (Fig. 2B and C (Fig. 2B, lower panel) and observed inhibition of monocyte migration on PAF exposure. Conversely, Rho-A activity decreased on PAF treatment but reversed by GSK inhibition (Fig. 2C, upper panel) . However, DN mutant over expression of Rho-A abolished GSK-VIII treated PAF induced monocyte migration in THP-1 cells (Fig. 2C, lower panel) 
Fig. 1 (A) Shows fold changes in monocyte migration responses to PAF in THP-1 cells and ND monocytes at 1 hr (open box) and 2 hrs (closed box). *P Ͻ 0.01 versus corresponding times in control (CT). (n ϭ 6 ND individuals). (B) Shows effects of AKT inhibition by AKT-IV on PAF induced monocyte migration on THP-1 and ND monocytes (n ϭ 6 ND individuals). *P Ͻ 0.01 versus corresponding times in control (CT). (C) Shows
Interplay of AKT-GSK axis on monocyte activation
GSK inhibition increases phosphorylation of AKT and migration in PAF stimulated monocytes (Fig. 3A-C) We have shown that AKT inhibition decreases monocyte migration (Fig. 1B and C) and phosphorylation of GSK-3␤S 9 (Fig. 1D) . In (Fig. 3C) . The mechanism by which this occurs requires further investigation.
contrast, inhibition of GSK phosphorylation by GSK-VIII paradoxically stimulates monocyte migration (Fig. 2A). To elucidate this further, we examined AKT phosphorylation of THP-1 monocytes after inhibition of GSK followed by PAF treatment. We demonstrate
Fig. 2 (A) Shows dose-dependent effects of GSK-VIII on GSK serine 9 phosphorylation in THP-1 cells (upper panel). Shows effects of GSK inhibition by GSK-VIII on PAF activated monocyte migration in THP-1 and ND monocytes (lower panel). *P Ͻ 0.01 versus corresponding time in PAF treated cells. (n ϭ 6 ND individuals). (B) Shows effect of GSK-VIII on PAF induced Rac-1 activation and monocyte migration in THP-1 cells with and without DN Rac-1 transfection. *P Ͻ 0.01 versus controls and DN Rac-1 mutant. (C) Shows effect of GSK-VIII on PAF induced Rho-A inactivation and monocyte migration in THP-1 cells with and without DN Rho-A transfection. *P Ͻ 0.01 versus DN Rho-A mutant. that GSK inhibition by GSK-VIII (Fig. 3A, upper panel) enhance AKT phosphorylation that was further quantified by image analyses (Fig. 3A, lower panel). A similar phenomenon was observed upon sense-antisense GSK oligonucleotide expression in ND monocytes following PAF stimulation (Fig. 3B). A likely explanation for this intriguing observation could be that GSK inhibition, somehow promotes cell signalling through phosphorylation of both AKT and active Rho-A (as validated in Fig. 2C), thereby augmenting migration. Additionally, we observed increased monocyte migration on GSK antisense transfection with and without PAF stimulation in ND monocytes
Unraveling of GSK inhibitory pathway
Role of ARAP3 on Rho-A activity by GSK inhibition (Fig. 4A) Fig. 2C ). (Fig. 5, lower panel) . These
To determine the molecular signalling involved following GSK inhibition we tested Rho-A activity by ELISA after knocking down ARAP3 (Rho-GAP) in ND human monocyte. In the control SiRNA experiment we observed that PAF down-regulates Rho-A activity which was reversed upon GSK inhibition (as in
In contrast, we observed enhanced Rho-A activity on ARAP3 knockout at baseline (i.e. without PAF), but following PAF exposure Rho-A activity was reduced that was partially reversed on GSK inhibition.
Role of AKT on GSK inhibitor induced Rho-A activity (Fig. 4B) We observed that AKT inhibition further down-regulates PAF
Fig. 3 (A) Shows effect of GSK-VIII and AKT-IV on PAF activated monocyte expressions for phospho-AKT in THP-1 cells. *P Ͻ 0.01 versus PAF stimulated AKT phosphorylation. (B) Shows effects of GSK sense and antisense on AKT phosphorylation with and without PAF in ND monocytes. (C) Shows effects of GSK sense and antisense on monocyte migration with and without PAF in ND monocytes at 1 (open bars) and 2 hrs (closed bars) (n ϭ 6 ND individuals). observations confirmed our earlier findings on monocyte migration assays (please see Figs 2C and 3C).
Interplay of AKT-GSK axis on monocyte activation in type 2 diabetes
Determination of differential phosphoprotein expression in PAF activated monocyte (Fig. 6A [13, 25] .
AKT-GSK crosstalk in PAF induced DM monocyte signalling (Fig. 6B) DM monocytes show increased GSK phosphorylation on PAF stimulation thus confirming the kinomics data. This effect was totally abolished by AKT inhibition and also down-regulated by GSK inhibition. Image densitometry analysis is confirmatory.
Effect of GSK inhibition on PAF induced diabetic monocyte migration (Fig. 6C) We found enhanced monocyte migration following GSK inhibition in DM individuals at both 1 and 2 hrs when compared to ND monocytes.
Effect of GSK antisense on AKT phosphorylation and monocyte activation in DM monocytes (Fig. 6D or dementia of Alzheimer's will need to be used with caution and deserve further study. Figure 7 shows putative signaling pathway. Furthermore, we did not rely solely on AKT and GSK inhibitors but also confirmed the findings through use of genetic manipulations of these kinases and small GTPases on monocytes.
Transendothelial monocyte migration is a vital initial step towards the development of atherosclerosis. This leads to differentiation of these monocytes into macrophages, formation of foam cells and release of inflammatory cytokines causing disruption of vascular integrity and plaque formation [26]. The current data highlight the cross-talk between crucial signalling molecules, viz. AKT and GSK-3␤ on monocyte migration in individuals with and without DM. We have demonstrated that (i) PAF stimulated monocyte activity is mediated through AKT-GSK axis; (ii) PAF stimulates monocyte migration and transendothelial migration through enhancement of downstream Rac-1 activity and inhibition of Rho-A activity; (iii) inhibition of GSK-3␤ phosphorylation leads to paradoxical stimulation of AKT phosphorylation that in turn stimulates monocyte migration via a GSK independent pathway; (iv) DM enhances these processes causing augmented monocyte migration on inhibition of GSK-3␤ phosphorylation.
PAF and atherogenesis are closely linked. Elevated levels of plasma and urinary PAF can be found in several disease states known to be associated with atherosclerosis including diabetes [3, 7] . [12] . Insulin is the classic ligand that inhibits GSK-3 through activation of AKT [27] , stimulating glycogen synthesis in liver and muscle cells, enhancing glucose uptake and lowering hepatic glucose production, hence fasting hyperglycaemia. GSK-3 is also involved in maintenance of cellular motility in neuronal tissues, epithelial cells and keratinocytes [11] . However, to our knowledge, there have been no prior studies investigating the role of GSK-3 on monocyte activity and migration.
Our data reveal that PAF stimulation results in migration of THP-1, ND and DM monocytes through phosphorylation of AKT and GSK-3␤ leading to Rac-1 activation. These finding seems to be in contrast to a recent report [28] in THP-1 macrophages that showed no change in Rac-1 activity on PAF stimulation but is in concordance to a prior report that showed stimulation of Rac-1 upon PAF exposure in neutrophils [29] . These conflicting reports may represent cell specific responses to PAF.
It is noteworthy that our data suggest an intriguing interaction between GSK [32] . The questions however remain as to the mechanism by which GSK influences the activities of the small GTPases [33] . As Rho-A is a small GTPase whereas AKT is a kinase, it is very unlikely that AKT directly Fig. 4(A) (Fig. 4B) and consequent migration (Fig. 1B and C) .
AKT, a serine-threonine kinase, plays a diverse role in cell migration. Current data suggest a prominent role of AKT on PAF induced monocyte migration through activation of small GTPases akin to a recent report [35] . However, AKT has potentially complex and mutually antagonistic effects on angiogenesis and atherogenesis [36] . It 
